Navigation Links
Bionovo Announces Decision to Explore Strategic Options and to Delay Announcement of Financial Results for 2011
Date:2/21/2012

EMERYVILLE, Calif., Feb. 21, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform:  BNVI.PK), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced its decision to explore strategic options.  As a result of this decision, the Company has decided to delay the announcement of its financial results for the year ended December 31, 2011, previously planned for today, to a later date.  The Company will provide an update for the release of its 2011 financial results within the next two weeks.

(Logo: http://photos.prnewswire.com/prnh/20111110/SF04662LOGO)

"We believe Menerba, our drug for the treatment of menopausal hot flashes currently in a Phase 3 trial, is a very valuable asset and we are focusing all of our efforts to complete that clinical trial," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "We are pursuing financial options to fund completion of the pivotal trial, but the outcome of those efforts cannot be assured.  We have therefore decided to explore in parallel, strategic options that may provide more value to our shareholders and ensure the continued development of Bionovo's products."

The Company has engaged Cowen and Company to assist Bionovo to explore its strategic options.

The Company will need to obtain substantial amounts of cash to achieve its objectives of internally developing drugs.  The Company does not currently have adequate internal liquidity to meet its cash needs in the near term including completion of the ongoing Phase 3 trial for Menerba.  If sufficient additional funds are not received in the near term, the Company may not be able to execute its business plan and may need to significantly curtail or cease operations.

About Bionovo, Inc.'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo to Host Conference Call to Discuss 2011 Highlights and Year-End Financial Results
2. Bionovo Announces Third Quarter 2011 Highlights and Financial Results
3. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
4. Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society
5. Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaqs Bid Price Rule
6. CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results
7. Bionovo Announces Second Quarter 2011 Highlights and Financial Results
8. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
9. Bionovo to Announce First Quarter Financial Results on Wednesday, May 11, 2011
10. Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
11. Bionovo Announces 2010 Highlights and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
(Date:11/24/2014)... (NYSE: CRY ), a leading medical device and ... today that it will participate in the upcoming 26 th ... 2014 at The New York Palace Hotel in ... of the Company,s presentation is scheduled to begin at 1:30 ... by Pat Mackin , President and Chief Executive Officer.The ...
(Date:11/24/2014)... Nov. 24, 2014 /PRNewswire/ - Milestone Pharmaceuticals, Inc. today ... in Melbourne, Australia of ... potential treatment of paroxysmal supraventricular tachycardia (PSVT).  The ... was well tolerated at single doses up to ... profile, desirable PK properties including rapid onset, and ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3
... second-tranche investment-, CAMBRIDGE, Mass., April 2, 2008 ... patient enrollment into its,Phase II clinical trial of ... osteoporosis. The Phase II dose-finding study is designed ... new bone for the treatment,of osteoporosis in postmenopausal ...
... LAUSANNE, Switzerland, and POMEZIA, Italy, April 2 ... Efficacy Results, Debiopharm Group (Debiopharm), a ... medical conditions, particularly,oncology and cardiology, and sigma-tau ... pharmaceutical group, today presented,positive efficacy results of ...
Cached Medicine Technology:Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis 2Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure 2Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure 3
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Parents need to take ... concussions, an expert warns. Parents must make sure ... standard, Dr. David Dodick, chair of the American Migraine ... Clinic College of Medicine in Scottsdale, Ariz. in an ... release. Any coach involved with teens sports needs ...
(Date:11/24/2014)... 24, 2014 Global electrophysiology devices ... by 2020, according to a new study by ... cardiac arrhythmias clubbed with growing global geriatric population ... Though still in the budding stage, the electrophysiology ... usage rates in the recent times, with physicians ...
(Date:11/24/2014)... Residents of retirement communities in Ohio and ... GOT TALENT, an annual online talent competition and showcase ... classic crooners, to seniors partying on a “night on ... living young. , “SENIORS GOT TALENT, while still having ... has always been about highlighting the vibrancy of being ...
(Date:11/24/2014)... Westbury, New York (PRWEB) November 24, 2014 ... recently contacted by the Family and Children's Association ... products such as soap, shampoo, mouthwash and other such ... senior citizens who are home bound, living in nursing ... are intended to greatly enhance the well being of ...
(Date:11/24/2014)... 2014 SafeHandles™ announced that they will ... Ed Begley Jr, airing via Discovery Channel. Dates and ... a passive, non-invasive, replaceable, and affordable germ protective device. ... shrinkable sleeves and adhesives to promote hand hygiene in ... core of SafeHandles is the desire to make a ...
Breaking Medicine News(10 mins):Health News:Parents Need to Take Lead on Teen Concussion Prevention 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2
... SETO Holdings, Inc. (Pink Sheets: SETO) announced that it signed ... (1) to issue shares of its Common Stock to acquire ... ("AHC"), a Maryland corporation which provides hearing services and retails ... Virginia, and (2) to sell all of SETO,s current businesses, ...
... how that happens may lead to ways around it, ... Temozolomide, a standard treatment for brain cancer, may boost ... more likely, a new study suggests. , The research ... City, have identified cells in brain tumors called gliomas ...
... Company Records 172% Year over Year Revenue Growth and ... Insulet,s International ExpansionBrian Roberts Appointed CFOBEDFORD, Mass., March 5 ... leader in tubing-free insulin pump technology with its OmniPod(R) ... fourth quarter and full year ended December 31, 2008. ...
... SEATTLE, March 5 Trubion Pharmaceuticals Inc. (Nasdaq: ... issue earnings results for the fourth quarter and year ... on March 12, 2009. The company,s earnings conference call ... Pacific Time, 5 p.m. Eastern Time. Both live events ...
... editors of the Harvard Health Letter , in consultation with the ... health care spending, saving society--and perhaps yourself--some money , ... Boston, MA ... will falter unless health care spending is brought under control. Moreover, even ...
... OpportunitiesHARRISBURG, Pa., March 5 Insurance Commissioner ... off from a job that offered health insurance to ... them with relief on premiums and that now is ... want to let Pennsylvanians know that additional help in ...
Cached Medicine News:Health News:SETO Holdings, Inc. Signs Letter of Intent to Dispose of all its Existing Businesses and Acquire Advanced Hearing Centers, Inc.; New Management to be Installed. 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 2Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 4Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 5Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 6Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 7Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 8Health News:Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 3Health News:Pennsylvanians Encouraged to Take Another Look at COBRA Options 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: